News | December 23, 2025
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
The company also reported significant progress toward its internally defined Sustainable Development Goals
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Subscribe To Our Newsletter & Stay Updated
